T2-high asthma phenotypes across lifespan.
Nicole MaisonJimmy OmonySabina IlliDominik ThieleChrysanthi SkevakiAnna-Maria DittrichThomas BahmerKlaus Friedrich RabeMarkus WeckmannChristine HappleBianca SchaubMeike MeyerSvenja FothErnst RietschelHarald RenzGesine HansenMatthias Volkmar KoppErika Von MutiusRuth Grychtolnull nullnull nullOliver FuchsBarbara RoeslerNils WelcheringNaschla Kohistani-GreifJohanna KurzKatja Landgraf-RaufKristina LaubhahnClaudia LieblMarkus EgeAlexander HoseEsther ZeitlmannMira BerbigCarola MarziChristina SchaubergerUlrich ZisslerCarsten Schmidt-WeberIsabell RicklefsGesa DiekmannLena LiboschikGesche VoigtLaila SultanseiGyde NissenInke R KönigAnne-Marie KirstenFrauke PedersenHenrik WatzBenjamin WaschkiChristian HerzmannMustafa AbdoHeike BillerKaroline I GaedeXenia BovermannAlena SteinmetzBerrit Liselotte HusstedtCatharina NitscheVera VeithMarlen SzewczykFolke BrinkmannAydin MalikNicolaus SchwerkChristian DopferMareike PriceAdan Chari JirmoAnika HabenerDavid S DeLucaSvenja GaedckeBin LiuMifflin-Rae CalveronStefanie WeberTom SchildbergSilke van Koningsbruggen-RietschelMiguel AlcazarPublished in: The European respiratory journal (2022)
Using easily accessible biomarkers, patients with T2-high asthma can be identified across all ages delineating a distinct phenotype. These patients may benefit from therapy with biologicals even at a younger age.